Bagsværd, Denmark, 7 July 2014 - On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK
15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014.
Since the announcement as of 1 July 2014, the following transactions have been made under the programme:
Accumulated, last announcement 9,786,000 2,354,700,476
1 July 2014 230,000 249.66 57,422,191
2 July 2014 275,000 253.00 69,573,818
3 July 2014 240,000 253.67 60,880,248
4 July 2014 210,000 253.40 53,213,643
Accumulated under the programme 10,741,000 2,595,790,375
With the transactions stated above, Novo Nordisk owns a total of 29,178,014 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 4 July 2014, Novo Nordisk has repurchased a total of 26,174,995 B shares equal to a transaction value of DKK
Novo Nordisk A/S
+45 4444 8888
24 25 67 90
Company announcement No 42 / 2014
Page 2 of 2
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately
40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's
B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.